Compare SNOA & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | XBIO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.2M |
| IPO Year | 2006 | N/A |
| Metric | SNOA | XBIO |
|---|---|---|
| Price | $2.54 | $2.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.4K | ★ 18.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,288,000.00 | N/A |
| Revenue This Year | $23.00 | $1.99 |
| Revenue Next Year | $24.59 | $20.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.19 | N/A |
| 52 Week Low | $1.77 | $1.90 |
| 52 Week High | $6.92 | $13.93 |
| Indicator | SNOA | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 60.82 |
| Support Level | N/A | $2.47 |
| Resistance Level | $3.85 | $2.76 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 45.10 | 93.33 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.